compounsing semaglutide ending fda compounding news october 2025 Drug compounders sue over declaration Wegovy shortage FDA cracks down on weight-loss FDA Ends Compounded GLP-1s: What

The primary goal of treatment should extend beyond weight loss to encompass the preservation of lean mass, improvement in metabolic health, and long-term prevention of obesity-related complications [7]

For CJC-1295 specifically, the most direct human evidence is endocrine: increased GH and IGF-1, particularly with the DAC-modified analog. Why it matters: CJC-1295 is relevant to body-composition research because it activates a pathway involved in lean tissue signaling, fat metabolism, and tissue remodeling

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been approved to help treat and manage type II diabetes

Those with chronic stress or poor lifestyle habits